DRUG COST ANALYSIS UNDER CAPITATION PAYMENT SYSTEM IN DAERAH ISTIMEWA YOGYAKARTA PROVINCE, INDONESIA
Penulis/Author
Prof. Dr. Susi Ari Kristina, S.Farm., M.Kes., Apt. (2); Prof. dr. Ali Ghufron Mukti, M.Sc., Ph.D. (3); Prof. Dr. Satibi, S.Si., M.Si. Apt. (4)
Tanggal/Date
5 2020
Kata Kunci/Keyword
Abstrak/Abstract
This study aimed to analyze the capitation payment utilization and expenditure of drug
costs in public and private primary health care (PHC). This study was a cross-sectional study with
quantitative approach of data collection that was done from January 2016 to December 2016 at 5 private and
5 public PHC, evaluating utilization and expenditure data prescription cost in Yogyakarta city and Sleman
district, Indonesia. We performed Mann-Whitney and Kruskal-Wallis analysis to determine differences in
utilization and expenditure of drug cost between private and public PHC. The most prevalent diseases found
based on the type of PHC was pulpitis (12.5%) while in private PHC was an acute upper respiratory
infection (13.5%). Characteristic of patients visited was female (68%), 46-55 age group (17%). The cost
used in health services were IDR 16,093 (77%) for patient examination and services and IDR 5,097 (23%)
for the drug. There were statistically difference for total cost of three diseases, including
hypercholesterolemia (p=0.008); acute upper respiratory infection (p= 0.023); and functional dyspepsia (p=
0.015). The highest drug cost based on diseases was refractory anemia (IDR 18,885). The proportion of drug
cost was about 23% of the total capitation fund received by PHCs. Drug costs in the capitation system at the
private first level health facilities tend to be higher than in the public facilities. Moreover, it is lower than the
international standard suggested by WHO. It is recommended to evaluate the capitation system especially
the rational proportion of health expenditure to enhance the quality of care.
